Intra-Cellular Therapies, Inc. ITCI
131.87 0.00 (+0.00%)
At closeApr 2, 2025, 4:00 PM EDT
131.87 Day range 131.87
52-week range unavailable
- YTD
- +57.89%
- 1 year
- +97.80%
- Market cap
- 14.05B
- Revenue (ttm)
- 680.85M
- Profit margin
- -10.97%
- Shares out
- 106.52M
- Forward P/E
- 507.19
- YTD return
- +57.89%
- 1-year return
- +97.80%
- Volume
- 16.04M
- Open
- 131.87
- Previous close
- 131.87
- Day's range
- 131.87 – 131.87
- Beta
- 0.46
- Analysts
- Hold
- Price target
- 132.00 (+0.1%)
2Y +42.63 (+47.77%)
Key statistics
- Enterprise value
- 13.04B
- PEG ratio
- 0.00
- Price / sales
- 20.63
- Price / book
- 12.20
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 50.80%
- Free cash flow
- -63.55M
- Total cash
- 1.00B
- Total debt
- 16.98M
- Return on equity
- -8.58%
- Short % of float
- 2.54%
- 50-day average
- 129.34
- 200-day average
- 93.12
Analyst view
Consensus: hold
Hold
Price target (mean) 132.00
Ratings (0m) 7 2 buy · 5 hold · 0 sell
- Strong buy1
- Buy1
- Hold5
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.10.
Financials — quick view
ITCI Revenue — quarterly 199.22M
ITCI Net income — quarterly -16.89M
ITCI EPS — quarterly -0.15
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 2, 2025 | Cantor Fitzgerald | reit | Neutral | Neutral |
| Feb 24, 2025 | Mizuho | down | Outperform | Neutral |
| Feb 21, 2025 | Needham | reit | Hold | Hold |
| Jan 31, 2025 | Canaccord Genuity | down | Buy | Hold |
| Jan 22, 2025 | RBC Capital | down | Outperform | Sector Perform |
| Jan 14, 2025 | Piper Sandler | down | Overweight | Neutral |
About Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company that develops and commercializes therapeutics and small molecule drugs for central nervous system (CNS), neuropsychiatric, and neurological disorders. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It distributes its products through third-party wholesale drug distributors. The company was founded in 2002 and is based in Bedminster, New Jersey. As of April 2, 2025, Intra-Cellular Therapies, Inc. operates as a subsidiary of Johnson & Johnson Innovative Medicine.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- intracellulartherapies.com
News
The Year-End 2025 Biotech Rally And What It Means For 2026 
Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update 
INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI 
ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-cellular Therapies, Inc. Is Fair to Shareholders 
ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales 
Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates 
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results 
Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last? 
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN and ITCI on Behalf of Shareholders 
Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer
Your note
Sign in to keep a note on ITCI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DURGAM SURESH K. | Officer | Conversion of Exercise of derivative security | Mar 9, 2025 | 42,913 |
| HALSTEAD MICHAEL I. | President | Conversion of Exercise of derivative security | Mar 9, 2025 | 21,307 |
| HINELINE LAWRENCE J | Chief Financial Officer | Sale | Mar 10, 2024 | 0 |
| MARCUS JOEL S | Director | Conversion of Exercise of derivative security | Feb 23, 2025 | 58,238 |
| MATES SHARON | Chief Executive Officer | Stock Gift | Mar 25, 2025 | 1,135,240 |
| NEUMANN MARK | Officer | Conversion of Exercise of derivative security | Mar 9, 2025 | 52,811 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 10.40% | 11,076,445 | 1.46B | Dec 30, 2024 |
| Vanguard Group Inc | 9.13% | 9,721,360 | 1.28B | Dec 30, 2024 |
| Blackrock Inc. | 5.74% | 6,112,723 | 806.08M | Dec 30, 2024 |
| JPMORGAN CHASE & CO | 4.81% | 5,126,092 | 675.98M | Dec 30, 2024 |
| Wasatch Advisors LP | 3.05% | 3,248,821 | 428.42M | Dec 30, 2024 |
| NORGES BANK | 3.02% | 3,212,964 | 423.69M | Dec 30, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.97% | 3,168,174 | 417.79M | Dec 30, 2024 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.41% | 2,565,294 | 338.29M | Dec 30, 2024 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.40% | 1,492,246 | 196.78M | Dec 30, 2024 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.36% | 1,452,407 | 191.53M | Dec 30, 2024 |
| JPMorgan Trust II-JPMorgan Mid Cap Growth Fund | 1.23% | 1,310,033 | 172.75M | Dec 30, 2024 |
| Fidelity Contrafund | 1.13% | 1,204,409 | 158.83M | Feb 27, 2025 |